sphingotec LLC announced today that the results of two studies examining the association between proenkephalin (pro-ENK) and incident breast cancer were published online in the Journal of Clinical…
sphingotec, LLC, a developer of predictive diagnostic tests for cancer, cardiovascular diseases and kidney function, today announced the results of a survey gauging women’s understanding of breast…
Biotech company to present how biomarkers improve breast cancer risk prediction in women under hormone replacement therapy. Cambridge, Mass. – Feb. 4, 2015 – sphingotec LLC announced today that the…
SphingoTec GmbH, headquartered in Hennigsdorf, Germany with U.S. operations in Cambridge, Massachusetts, today announced that it has out-licensed two of its biomarker assays—sphingotest® pro-NT and…
